Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Real-time Estimate Cboe BZX  -  11:10 2022-11-28 am EST
7.385 USD   -2.83%
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics Reports Granting of Inducement Award

09/20/2022 | 05:54pm EST

NEWARK, Calif., Sept. 20, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2022, it issued an inducement award to Pedro Oyuela, M.D., the Company's recently hired Vice President of Pharmacovigilance, in accordance with the terms of Dr. Oyuela's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The inducement award consists of an option to purchase 35,000 shares of Protagonist Therapeutics common stock and has a ten-year term. The exercise price of the options is $8.27, which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on September 15, 2022. The shares subject to the option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of Dr. Oyuela's date of hire and the remainder vesting in equal monthly installments over three years thereafter. The award was approved by the compensation committee of the Company's board of directors and was granted as a material inducement to Dr. Oyuela's entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist Therapeutics

Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide, PN-943, and PN-235 in different stages of clinical development, all derived from the Company's proprietary technology platform. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate. VERIFY, the global Phase 3 registrational study of rusfertide in polycythemia vera, is currently underway. Protagonist is headquartered in Newark, California. For more information on Protagonist, please visit the Company's website at www.protagonist-inc.com

Protagonist Therapeutics, Inc.
 (PRNewsfoto/Protagonist Therapeutics Inc.)

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-reports-granting-of-inducement-award-301628986.html

SOURCE Protagonist Therapeutics, Inc.


ę PRNewswire 2022
All news about PROTAGONIST THERAPEUTICS, INC.
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintain..
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/08Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/08Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
PR
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
CI
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/25JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price ..
MT
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations